Boryung has begun global sales of the cytotoxic anticancer drug Taxotere (ingredient name docetaxel), for which it acquired ...
Purpose: The permeability of 13 different gloves to 13 cytotoxic agents under controlled dynamic conditions is described. Methods: Thirteen cytotoxic agents were prepared at the highest concentrations ...
Grace Liu (left) is a Technical Account Manager at Sino Biological US Inc. (PA, USA). Grace joined Sino Biological in 2022, supporting CRO services and project management in the western and central US ...
The emergence of antibody-drug conjugates (ADCs) has seen them become a promising class of anticancer therapeutics, exhibiting better precision and reduced off-target toxicity in targeting cancer ...
The past decade in oncology has been marked by the rise of immunotherapy, which leverages the immune system to attack tumors. For many solid tumors, immune checkpoint inhibitors have supplanted ...
Antibody-drug conjugates (ADCs) represent an emerging class of therapeutics across solid tumor oncology and are already positioned as a cornerstone therapy for patients with urothelial carcinoma (UC).
As pharmaceutical companies embrace antibody-drug conjugates (ADCs) as a way to treat cancer, drug services providers are investing in capacity to meet the companies’ manufacturing needs.
The pharmaceutical industry's ongoing efforts to strengthen medicine traceability and combat counterfeit drugs could face significant implementation challenges if regulatory expansion moves ahead ...
In this interview, Grace Liu from Sino Biological shares her expertise on Antibody-Drug Conjugates (ADCs), a revolutionary cancer therapy combining precision targeting with potent cytotoxic drugs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results